thrombosis even in those patients where complete removal of thrombi is achieved during operation; of 5 patients who had complete clearance at thrombectomy, 2 rethrombosed within 72 hours.
Once deep vein thrombosis has occurred it seems likely that prevention of the late sequele can best be brought about by rapid and complete dissolution of thrombus so that valvular function is preserved. Streptokinase which actively lyses the thrombus seems to be the most effective agent for doing this provided the diagnosis can be made early, within 36 hours of onset. Heparin or Arvin causes slower dissolution of thrombi, and consequently valvular function is less satisfactory. Results were similarly disappointing in patients treated by thrombectomy.
The tentative conclusion at present is that the best and most effective treatment for deep vein thrombosis is active thrombolysis with an agent like streptokinase. Its side-effects and drawbacks are still being investigated.
[This material is a summary of one of four sections of the Hunterian Lecture delivered to the Royal College of Surgeons on March 20 1969 (see Kakkar 1969 Immunological methods for the treatment of malignant disease may be divided into two main groups, those which aim at increasing the patient's resistance to his tumour, and those where an extrinsic immunological attack is. launched against the tumour.
For methods in the first group to be applicable the tumour to be treated must possess specific antigens which serve as the point d'appui for the host's immune response. In animals a wide variety of neoplasms initially fulfil this condition (see Klein 1966 for a review). However, on progressive growth experimental tumours may either delete their specific antigens (Woodruff & Symes 1962a , Symes 1965 or induce a state of immunodepression in the host directed either against the tumour-specific antigens themselves (Stjernsward 1968) or, more generally, against unrelated third-party antigens (Linder 1962) .
At a clinical level, evidence for the possession of tumour-specific antigens, which has been gathered for experimental neoplasms mainly as a result of experiments involving the transplantation of tumours to isogenic hosts, is less clear. It is based on indirect evidence: for example, a correlation between lymphoid cell infiltration of breast carcinoma and a favourable prognosis (Black & Speer 1958) , the occurrence of circulating antibody detected by passive hemagglutination and indirect immunoflorescence in up to 25 % of patients with malignant melanomata (Mansell 1969) and, more speculatively, the occurrence of spontaneous regressions among human neoplasms of various types (Everson & Cole 1956 , Smithers 1962 .
There is, however, good evidence that patients with advanced carcinoma show a diminished response to third-party antigens (Southam 1965) .
Having thus emphasized that specific antigens are likely to be present, or capable of inducing an immune reaction by the host, only in neoplasms of recent origin, methods for increasing host resistance may be reviewed. They are summarized in Table 1 . With the exception of Mathe's work there have been few deliberate attempts to exploit Table I Methods for increasing the host's resistance to its tumour (1) Administration of stimulants to the immune system, for example Bacillus Calmette Gu6rin (BCG) (Old et al. 1961 , Math6 et al. 1969 or C. parvum (Woodruff & Boak 1966) (2) Surgical excision of the tumour (Symes 1963) (3) Excision of the tumourirradiation in vitro or destruction by other means consonant with preservation of antigenicityreimplantation (Finney et al. 1960) (4) Destruction of the tumour in situ, for example by ligation ofthe blood supply (Foley 1953), irradiation, or The immuogilly competent cells may or may not (Stuart 1962) be preceded by immunosuppressive therapy, given to the host, to promote sunrival of the cells the methods, but evidence from pexim ts in animals suggest that all are worthy of trial in appropriate circumstances. Surgical excision, which is the orthodox treatment for many-neoplasms in man, may also be a potent immunologic weapon. The marked reduction in tumour mass achieved thereby would seem likely to facilitate the host's reaction against any remaining-tumour cells, particularly when the relief of any concomitant immunodepression associated with tumour growth is considered. If this is true, it would be a powerful argument against the practice of administering cytotoxic drugs or irradiation in an attempt to destroy any tumour cells which remain, for lymphoid cells are preferentially destroyed by thes therapeutic agents. Furthermore, it is probable that those lymphoid cells most adjacent to igant cells are primarily responsible for any immune response against the tumour.
For advanced and otherwise hopeless cases of malignant disease, an attempt may be made to launch an extrinsic immunological attack on the tumour by adoptive transfer of immunologically competent cells from another individual. The methods available are summarized in Table 2 .
Some impetus was given to these attempts by the finding, in mice, of a direct -relation between the size of the tumour and the therapeutic effect of a given dose of foreign immunologically competent cells (Symes 1967) .
Cells immunized against the tumour to be treated have been found to be more effective than non-immunized cells, and this fact has provided the stimulus to use animals, pre-immunized against human tumours, as donors.
